Liquid Biopsy Market by Product & Service (Kits, Instruments), Circulating Biomarker (ctDNA, cfDNA, CTC), Technology (NGS, PCR), Application (Lung, Breast, Prostate Cancer), Sample Type (Blood, Urine, CSF), End User (Hospitals) - Global Forecast to 2030

The liquid biopsy market is projected to reach USD 7.05 billion by 2030 from USD 4.03 billion in 2025, at a CAGR of 11.8% during the forecast period. Liquid biopsy offers several key advantages over traditional biopsy methods, including its non-invasive nature, lower procedural costs, the ability to monitor disease progression more easily, and the potential for detecting cancer at early stages. These benefits have contributed to growing acceptance among end users. As a result, the increasing adoption and recognition of liquid biopsy's clinical value are expected to fuel market growth during the forecast period.

By clinical application, the early cancer screening segment is expected to grow at the highest CAGR during the forecast period.

The liquid biopsy market is segmented by clinical application into early cancer screening, therapy selection, treatment monitoring, and recurrence monitoring. The early cancer screening segment is projected to register the highest CAGR during the forecast period. The high growth rate of this segment is driven by the rising incidence of cancer, the increasing importance of early disease diagnosis, and the development of effective oncology therapeutics for treatment. Rising research efforts & funding dedicated to early detection are accelerating the development of liquid biopsy technologies.

By sample type, the blood sample segment accounted for the largest market share in 2024.

Based on sample type, the liquid biopsy market is segmented into blood and other sample types. In 2024, the blood sample segment accounted for the largest share of the market. The large share of this segment is attributed to the ease of collection, minimal invasiveness, and its ability to provide comprehensive molecular insights from circulating biomarkers such as ctDNA, cfDNA, and CTCs. Blood-based sampling is safer, quicker, and more acceptable to patients than tissue biopsies, which has led to its widespread adoption in both research and diagnostics.

By region, the Asia Pacific is projected to grow at the highest CAGR during the forecast period.

The market is segmented by region into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific region is expected to grow at the highest CAGR during the forecast period. The high growth rate of this market is driven by the increasing prevalence of cancer, the rising healthcare expenditure, expanding access to advanced diagnostics, and the growing presence of international & local diagnostic companies. Additionally, supportive government initiatives for cancer screening programs and rising awareness of non-invasive diagnostic options are expected to contribute to market growth.

The break-up of the profile of primary participants in the liquid biopsy market:

• By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 – 30%
• By Designation: C-level - 27%, D-level - 18%, and Others - 55%
• By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America – 6%, and the Middle East & Africa- 4%

The key players in this market are Natera, Inc. (US), Guardant Health (US), Myriad Genetics, Inc. (US), Illumina, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), QIAGEN (Netherlands), Thermo Fisher Scientific Inc. (US), Bio-Rad Laboratories, Inc. (US), Exact Sciences Corporation (US), Sysmex Corporation (Japan), maxhealth (US), Personalis, Inc. (US), GRAIL, Inc. (US), Menarini-Silicon Biosystems (Italy), NeoGenomics. Laboratories (US), ANGLE plc (UK), Vortex Biotech Holdings (US), Bio-Techne (US), MedGenome (US), Mesa Labs, Inc. (US), Labcorp, Holdings Inc (US), Freenome, Holdings, Inc. (US), Strand (India), LungLife Al, Inc. (US), Lucence Health Inc. (US), and New Day Diagnostics, LLC (US).

Research Coverage:

This research report categorizes the liquid biopsy market by product & service (assay kits, instruments, and services), circulating biomarker type (circulating tumor cells, circulating tumor DNA, cell-free DNA, extracellular vesicles, and other circulating biomarkers), technology (multi-gene parallel analysis using NGS and single-gene analysis using PCR & microarrays), application [cancer applications (lung cancer, breast cancer, colorectal cancer, prostate cancer, melanoma, and other cancers) and non-cancer applications (non-invasive prenatal testing, organ transplantation, and infectious disease testing]), clinical application (early cancer screening, therapy selection, treatment monitoring, and recurrence monitoring), sample type (blood and other sample types), end user (reference laboratories, hospitals & physician laboratories, academic & research centers, and other end users), and region (North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa). The report's scope covers detailed information regarding the leading factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the liquid biopsy market. A thorough analysis of the key industry players has provided insights into their business overview, solutions, key strategies, acquisitions, and agreements. New product launches and recent developments associated with the liquid biopsy market. This report covers a competitive analysis of upcoming startups in the liquid biopsy market ecosystem.

Reasons to buy this report:

The report will help market leaders/new entrants with information on the closest approximations of the revenue numbers for the overall liquid biopsy market and the subsegments. It will also help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key market drivers, restraints, opportunities, and challenges.

The report provides insights into the following pointers:

• Analysis of key drivers (Rising incidence and prevalence of cancer, cancer awareness initiatives undertaken by global health organizations, and increased benefits of liquid biopsy over traditional biopsy procedures), opportunities (Growing significance of companion diagnostics and growth opportunities in emerging countries), restraints (Lower sensitivity of specific liquid biopsy procedures), and challenges (Unclear reimbursement scenario) influencing the growth of the liquid biopsy market.
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the liquid biopsy market.
• Market Development: Comprehensive information about lucrative markets – the report analyses the liquid biopsy market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the liquid biopsy market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings of leading players like Natera, Inc. (US), Guardant Health (US), Myriad Genetics, Inc. (US), Illumina, Inc. (US), and F. Hoffmann-La Roche Ltd. (Switzerland).

Show more